Top Page
CervoMed
(NASDAQ:CRVO)
CervoMed (CRVO) vs. S&P 500 (SPY)
CervoMed Business Overview & Revenue Model
CervoMed Financial Statement Overview
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 0.00 | 7.14M | 0.00 | 0.00 | 0.00 | Gross Profit |
| 0.00 | -1.29M | -1.34M | -93.42K | -103.17K | EBIT |
| -18.23M | -7.81M | -3.48M | -16.04M | -15.97M | EBITDA |
| -18.23M | -2.17M | 0.00 | -24.45M | -15.76M | Net Income Common Stockholders |
| -16.29M | -2.17M | -5.80M | -24.10M | -14.19M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 38.92M | 7.79M | 4.09M | 37.31M | 18.52M | Total Assets |
| 43.08M | 9.97M | 4.16M | 37.84M | 29.55M | Total Debt |
| 0.00 | 0.00 | 36.70M | 10.03M | 149.16K | Net Debt |
| -9.00M | -7.79M | 32.61M | -27.29M | -18.37M | Total Liabilities |
| 3.88M | 2.60M | 37.44M | 2.93M | 4.73M | Stockholders Equity |
| 39.20M | 7.38M | -33.29M | 34.91M | 24.81M |
| Cash Flow | Free Cash Flow | |||
| -16.53M | -7.45M | -2.57M | -14.50M | -13.55M | Operating Cash Flow |
| -16.53M | -7.45M | -2.57M | -14.50M | -13.55M | Investing Cash Flow |
| -28.66M | 0.00 | -12.24M | 4.00K | 0.00 | Financing Cash Flow |
| 46.40M | 11.15M | 0.00 | 33.30M | 17.89M |
CervoMed Technical Analysis
CervoMed Risk Analysis
CervoMed Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $5.32B | 3.32 | -40.25% | 2.90% | 17.93% | 2.14% | |
49 Neutral | $86.93M | ― | -58.80% | ― | -100.00% | -24.28% | |
47 Neutral | $76.58M | ― | -69.95% | ― | 142.42% | 53.38% | |
40 Underperform | $87.72M | ― | -46.26% | ― | ― | -61.95% | |
38 Underperform | $98.46M | ― | -44.03% | ― | ― | 86.65% | |
35 Underperform | $92.76M | ― | -70.13% | ― | ― | 1.27% | |
32 Underperform | $89.72M | ― | 48.74% | ― | ― | -1.60% |
CervoMed Corporate Events
CervoMed Inc. has announced significant executive appointments and changes effective in 2025. Kelly Blackburn has been promoted to Executive Vice President, Clinical Development, with an amended employment agreement detailing her compensation and severance provisions. Mark De Rosch has been appointed as Executive Vice President, Regulatory and Government Affairs and Program Management, with a comprehensive employment agreement outlining his salary and benefits. Additionally, the company has finalized a separation agreement with Chief Operating Officer Robert J. Cobuzzi, Jr., whose employment will conclude in July 2025, including provisions for severance pay and stock option vesting. These changes reflect CervoMed’s strategic adjustments in its leadership team, potentially impacting its operational focus and stakeholder interests.
Spark’s Take on CRVO Stock
According to Spark, TipRanks’ AI Analyst, CRVO is a Neutral.
CervoMed’s stock is weighed down by financial instability, marked by persistent losses and cash flow challenges. The recent positive clinical trial results offer a significant potential upside, but the speculative nature of these developments coupled with valuation challenges tempers the outlook. While technical indicators show some short-term momentum, the overall financial health remains a concern.
To see Spark’s full report on CRVO stock, click here.
On April 2, 2025, CervoMed announced positive clinical results from the first sixteen weeks of the open-label extension phase of their RewinD-LB Phase 2b clinical trial for neflamapimod, a treatment for dementia with Lewy bodies. The trial showed that neflamapimod slowed clinical progression and reduced falls compared to controls, with improvements in cognitive fluctuations and working memory. These findings, presented at the AD/PD 2025 conference, support the potential of neflamapimod as a transformative therapy for patients with dementia with Lewy bodies, and CervoMed plans to engage with regulatory authorities to finalize Phase 3 plans.
Spark’s Take on CRVO Stock
According to Spark, TipRanks’ AI Analyst, CRVO is a Neutral.
CervoMed’s stock score is primarily impacted by its financial challenges, with no revenue and persistent losses. However, technical indicators suggest positive momentum, and recent positive clinical trial results may improve future prospects. Valuation poses challenges due to negative earnings, but the potential for clinical success offers a speculative upside.
To see Spark’s full report on CRVO stock, click here.
CervoMed has made available information about its business, clinical studies, development plans, and financial position on its website under the ‘Investors – Events and Presentations’ section. The company may use this information in various investor-related activities, but it does not commit to updating it publicly unless legally required.
On March 10, 2025, CervoMed Inc. announced positive results from the first 16 weeks of the extension phase of its Phase 2b RewinD-LB clinical trial for neflamapimod, aimed at treating dementia with Lewy bodies. The new batch of neflamapimod capsules showed improved plasma drug concentrations and significant improvements in clinical outcomes compared to old capsules and placebo, suggesting potential to alter the disease course. This development marks a significant step forward in the treatment of DLB, with the company planning to engage with regulatory authorities for Phase 3 trials.
On January 31, 2025, CervoMed provided an update on its development of neflamapimod for dementia with Lewy bodies, presented at the 8th International Lewy Body Dementia Conference. The RewinD-LB Phase 2b trial showed no significant differences between the neflamapimod and placebo groups during the 16-week double-blind phase, possibly due to the age of the drug batch. The company anticipates efficacy endpoint data from the open-label extension phase using newer capsules, which showed better plasma drug concentrations. These results will guide the next steps in neflamapimod’s development.